2022
Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis
Kayali S, Pasta A, Torres M, Jaffe A, Strazzabosco M, Marenco S, Giannini EG. Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis. Liver International 2022, 43: 8-17. PMID: 36102312, PMCID: PMC10087158, DOI: 10.1111/liv.15419.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsLiver transplant recipientsGraft rejectionOverall survivalICI therapyCheckpoint inhibitorsICI treatmentPooled analysisSystematic reviewDe novo malignanciesAcute graft rejectionDisease control rateRecurrent hepatocellular carcinomaShorter overall survivalGraft lossNovo malignanciesLiver transplantationLT recipientsTransplant recipientsAdvanced malignanciesProspective studyControl rateCase reportHepatocellular carcinomaPatients
2018
Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry
Belli LS, Perricone G, Adam R, Cortesi PA, Strazzabosco M, Facchetti R, Karam V, Salizzoni M, Andujar RL, Fondevila C, De Simone P, Morelli C, Fabregat-Prous J, Samuel D, Agarwaal K, Gonzales EM, Charco R, Zieniewicz K, De Carlis L, Duvoux C, Association A. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. Journal Of Hepatology 2018, 69: 810-817. PMID: 29940268, DOI: 10.1016/j.jhep.2018.06.010.Peer-Reviewed Original ResearchConceptsHepatitis C virusNon-alcoholic steatohepatitisHepatitis B virusEuropean Liver Transplant RegistryLiver transplantationSurvival of recipientsDAA eraLiver diseaseHepatocellular carcinomaEvolution of indicationsVirus infectionNumber of LTsHepatitis B virus infectionHepatitis C virus infectionAdult liver transplantationAdvent of DAAsImpact of DAAsLiver Transplant RegistrySecond-generation DAAsC virus infectionLiver transplant recipientsOutcomes of patientsB virus infectionThree-year survivalDAA treatment
2017
ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients
Belli LS, Duvoux C, Berenguer M, Berg T, Coilly A, Colle I, Fagiuoli S, Khoo S, Pageaux GP, Puoti M, Samuel D, Strazzabosco M. ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. Journal Of Hepatology 2017, 67: 585-602. PMID: 28323126, DOI: 10.1016/j.jhep.2017.03.006.Peer-Reviewed Original ResearchConceptsLiver transplantationHCV infectionConsensus statementUse of DAAsLiver transplant candidatesLiver transplant recipientsSevere renal failureRemarkable clinical improvementTransplant recipientsClinical improvementLT candidatesRenal failureTransplant candidatesDisease recurrenceNative liverUnusual complicationTransplant fieldDrug interactionsHCV- graftsWaiting listAntiviral agentsRecipientsHCVPatientsGraft
2008
Incidence and Management of Colorectal Cancer in Liver Transplant Recipients
Nishihori T, Strazzabosco M, Saif MW. Incidence and Management of Colorectal Cancer in Liver Transplant Recipients. Clinical Colorectal Cancer 2008, 7: 260-266. PMID: 18650194, PMCID: PMC3755274, DOI: 10.3816/ccc.2008.n.033.Peer-Reviewed Original ResearchConceptsLiver transplant recipientsTransplant recipientsColorectal cancerLiver transplantationPatient populationColon cancerDe novo colorectal cancerDe novo malignanciesLong-term immunosuppressionMetastatic colorectal cancerPrimary sclerosing cholangitisInflammatory bowel diseaseMajor health concernChronic rejectionNovo malignanciesProlonged immunosuppressionSclerosing cholangitisPosttransplantation periodBiologic agentsBowel diseaseCombination chemotherapyProphylactic colectomyOverall incidenceCommon malignancyLymphoproliferative disease
1998
Cerebral aspergillosis in a liver transplant recipient: a case report of long-term survival after combined treatment with liposomal amphotericin B and surgery
Iemmolo R, Rossanese A, Rotilio A, Mattisi G, Gerunda G, Merenda R, Neri D, Crepaldi G, Strazzabosco M. Cerebral aspergillosis in a liver transplant recipient: a case report of long-term survival after combined treatment with liposomal amphotericin B and surgery. Journal Of Hepatology 1998, 28: 518-522. PMID: 9551693, DOI: 10.1016/s0168-8278(98)80329-2.Peer-Reviewed Original ResearchConceptsLiver transplant recipientsLiposomal amphotericin BTransplant recipientsCerebral aspergillosisAmphotericin BLife-threatening complicationsLiposomal amphotericin B.Complication-free survivalRisk of recurrenceSystemic side effectsAspergillus fumigatus infectionLong-term survivalSurgical excisionCase reportFumigatus infectionLimited efficacyCerebrospinal fluidSide effectsMortality rateAmphotericin B.AspergillosisRecipientsSurvivalTreatmentFirst report
1997
Epstein-Barr virus-associated post-transplant lympho-proliferative disease of donor origin in liver transplant recipients
Strazzabosco M, Corneo B, Iemmolo R, Menin C, Gerunda G, Bonaldi L, Merenda R, Neri D, Poletti A, Montagna M, Del Mistro A, Faccioli A, D'Andrea E. Epstein-Barr virus-associated post-transplant lympho-proliferative disease of donor origin in liver transplant recipients. Journal Of Hepatology 1997, 26: 926-934. PMID: 9126809, DOI: 10.1016/s0168-8278(97)80262-0.Peer-Reviewed Original ResearchConceptsPost-transplant lymphoproliferative diseaseLiver transplant recipientsOrthotopic liver transplant recipientsLymphoproliferative diseaseTransplant recipientsDonor originB lymphocytesDonor B lymphocytesEBV-specific probesPost-transplant lymphomaOrthotopic liver transplantEpstein-Barr virus sequencesSolid organ transplantationPossible risk factorsLympho-proliferative diseaseNeoplastic B cellsLiver transplantEBV DNAHepatic hilumProspective studyHodgkin's lymphomaPolymerase chain reactionPotential complicationsRisk factorsReal incidence